The impact of baseline [−2]proPSA-related indices on the prediction of pathological reclassification at 1 year during active surveillance for low-risk prostate cancer: the Japanese multicenter study cohort

Pathologic Prostate Cancer Characteristics in Patients Eligible for Active Surveillance: A Head-to-Head Comparison of Contemporary Protocols

(2012) Viacheslav Iremashvili et al.   EUROPEAN UROLOGY

Association of [−2]proPSA with Biopsy Reclassification During Active Surveillance for Prostate Cancer

(2012) Jeffrey J. Tosoian et al.   JOURNAL OF UROLOGY

Prostate-Cancer Mortality at 11 Years of Follow-up

(2012) Fritz H. Schröder et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pathological Outcomes of Men Eligible for Active Surveillance After Undergoing Radical Prostatectomy: Are Results Predictable?

(2011) Turang Ed Behbahani et al.   Clinical Genitourinary Cancer

Preoperative Prostate-Specific Antigen Isoform p2PSA and Its Derivatives, %p2PSA and Prostate Health Index, Predict Pathologic Outcomes in Patients Undergoing Radical Prostatectomy for Prostate Cancer

(2011) Giorgio Guazzoni et al.   EUROPEAN UROLOGY

A Multicenter Study of [-2]Pro-Prostate Specific Antigen Combined With Prostate Specific Antigen and Free Prostate Specific Antigen for Prostate Cancer Detection in the 2.0 to 10.0 ng/ml Prostate Specific Antigen Range

(2011) William J. Catalona et al.   JOURNAL OF UROLOGY

Prostate-Specific Antigen (PSA) Isoform p2PSA in Combination with Total PSA and Free PSA Improves Diagnostic Accuracy in Prostate Cancer Detection

(2010) Flip H. Jansen et al.   EUROPEAN UROLOGY

Pathological Findings at Radical Prostatectomy in Japanese Prospective Active Surveillance Cohort

(2010) M. Sugimoto et al.   JAPANESE JOURNAL OF CLINICAL ONCOLOGY

Prostate-Specific Antigen Kinetics During Follow-Up Are an Unreliable Trigger for Intervention in a Prostate Cancer Surveillance Program

(2010) Ashley E. Ross et al.   JOURNAL OF CLINICAL ONCOLOGY

Mortality results from the Göteborg randomised population-based prostate-cancer screening trial

(2010) Jonas Hugosson et al.   LANCET ONCOLOGY